JPRN-UMIN000000647
Unknown
Phase 1
To evaluate safety and efficacy of intravitreal Bevaxizumab injection for intraocular neovasculalization - Intravitreal Bevaxizumab injection for intraocular neovasculalization
Department of Ophtalmology of Keio University Hospital0 sites10 target enrollmentMarch 22, 2007
ConditionsARMD,BRVO,CRVO,DR,CNV
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- ARMD,BRVO,CRVO,DR,CNV
- Sponsor
- Department of Ophtalmology of Keio University Hospital
- Enrollment
- 10
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Cr\>3\.0mg/dL anstable angina malignant arrhythmia HT:140/80mmHg\>
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Evaluation of safety and efficacy of intravitreal bevacizumab for macular edema, retinal or choroidal neovascularization or neovascular glaucoma - NDMacular oedemaMedDRA version: 6.1Level: HLGTClassification code 10047060EUCTR2006-002351-33-ITAZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
Active, not recruiting
Not Applicable
Evaluation of efficacy and safety of Intravitreal bevacizumab versus intravitreal bevacizumab combined with juxtascleral anecortave acetate for the treatment exudative age-related macular degeneration - IVB JSAEUCTR2006-003170-99-ITIVERSITA DEGLI STUDI DI UDINE
Completed
Not Applicable
Safety and effectiveness of intravitreal bevacizumab and ranibizumab injections for treatment of retinal disease patients: an observational studyretinal diseases or conditions that can be treated with bevacizumab or ranibizumab such as neovascular age-related macular degeneration (neovascular AMD),diabetic macular edema (DME),and macular edeneovascular age-related macular degeneration (neovascular AMD)diabetic macular edema (DME)retinal vein occlusion(RVO)TCTR20141002001Health Intervention and Technology Assessment Program (HITAP)6,399
Active, not recruiting
Not Applicable
Safety and efficacy of intravitreal injections of ranibizumab/Lucentis in combination with verteporfin photodynamic therapy (PDT) in patients with choroidal neovascularisation (CNV) secondary to age related macular degeneratioEUCTR2006-002977-33-SIniversity Eye Hospital10
Completed
Not Applicable
Evaluation of the efficacy and safety of intravitreal injection of ranibizumab every other month for age-related macular degeneratioage-related macular degenerationJPRN-UMIN000005691Department of Ophthalmology, Shiga University of Medical Science40